Lafaxor hard capsules 75mg Davipharm against depression, anxiety (3 blisters x 10 tablets)

Dosage form Box of 3 blisters x 10 tablets
Specifications Vendafaxine

Ingredient

Composition information	Content
Vendafaxine	75mg

Uses

indications

lafaxor with pharmaceutical substance is Venlafaxin, which is indicated for treatment of depression, including depression accompanied by anxiety, for internal and outpatient patients.

Pharmacological

venlafaxin, a selective recovery inhibitor Serotonin and norepinephrin, is a derivative of phenylethylamin that has antidepressant and anti -anxious effects. Venlafaxin's antidepressant and anxiety mechanism has not been fully understood, but it is related to the ability to enhance the neurotransmitter activity of the central nervous system.

venlafaxin and its active metabolites are O-Desmethylvenlafaxin (ODV), which are inhibitors that strongly recover serotonin and norepinephrin, and are weak inhibitors with dopamine recovery. In vitro research shows Venlafaxin and ODV have no significant affinity for the Cholinergic Muscarinic receptor, H1 histaminergic, or α-adrenergic.

Dynamic pharmacokinetics

at least 92% venlafaxin are absorbed after taking single dose venlafaxin. Absolute biological use is 40% to 45%. After drinking, most of the initial metabolic drugs in the liver to form mainly the metabolic substance with O-Desmethylfenlafaxin (ODV) activity. The formation of ODV through cytochrom P450 CYP2D6, ISOENZYM CYP3A4 is also involved in the metabolism of Venlafaxin. Other changing substances include N-Desmethidvenlafaxin and O-DidesmethylaFaxin.

time for vendaraxin and o-didesmethylvenlafaxin to reach the peak concentration in plasma is 2 and 4 hours after drinking. The ratio of venlafaxin is 27% and O-didesmethylvenlafaxin is 30%. The average selling time of venlafaxin and o-didesmethylvenlafaxin respectively 5 and 11 hours.

Most venlafaxin are eliminated in urine, mainly in the form of metabolites or in the form of freelance or in the form of a combination, about 2% are eliminated in feces. O-DidesmethylaLfaxin and Venlafaxin have been discovered in amniotic fluid and umbilical cord blood and passes through breast milk.

Before taking Lafaxor hard capsules 75mg Davipharm against depression, anxiety (3 blisters x 10 tablets)

How to use

Take oral use.

Dosage

In the treatment of depression, the initial dose is Venlafaxin 75 mg divided 2 to 3 times/day within 3 to 4 days, before increasing the dose to 75 mg/day. If necessary, after a few weeks the dose may increase to 150 mg/day. The maximum dose can be used is 375 mg. Each adjustment of the dose may increase maximum of 75 mg in a period of 2-4 days.

Patients with kidney failure or liver failure

Patients with renal impairment and/or liver failure need lower dose venlafaxin. Need to reduce 50% daily dose for patients with glomerular filtration index (GFR) below 30 ml/min/1.73m2. Due to the semi -cancellation time in Venlafaxin's plasma and its main metabolites lasted in severe renal failure, it was possible to use the entire one -time dose for the whole day.

The clearance by hemorrhage of both Venlafaxin and O-Desmethyl Venlaraxin on the body is low. However, Venlafaxin should be stopped for those who have to apply hematuria until the treatment is completed.

Patients with moderate liver failure with prothrombin time from 14 to 18 seconds need to be reduced by 50%. The lower dose is needed to be lower for people with liver failure.

Older people

No need to reduce the dose for elderly patients if only for age. However, like other antidepressants, need to be cautious when treating the elderly. For each individual, special attention should be paid to increasing the dose.

Note: The above dose is for reference only. Specific dosage depends on the condition and level of progression of the disease. For a suitable dose, you need to consult a doctor or medical specialist.What to do when overdose?

Symptoms

In the experiences after bringing the drug to the market, changing the electrocardiogram, increasing the ventricular rhythm and sinap, the heartbeat and epilepsy are recorded in cases of overdose of Venlafaxin, both when used alone as well as other drugs and/or alcohol. It is impossible to exclude the use of Venlafaxin alone is the only cause of death in the event of an overdose of death. Rarely see overdose venlafaxin along with other drugs and/or deadly alcohol.

Handling

Ensure ventilation, provide enough oxygen and fully ventilated. Heart rate check and live signs. Need supportive treatment and symptomatic treatment. It is possible to use activated carbon, causing vomiting or gastric lavage. No special antidote for Venlafaxin. Do not use hemolyte for both Venlafaxin and O-Desmethyl Venlafaxin because the clearing of the hemorrhage of both substances is low.

What to do when forgetting 1 dose?

Not recorded.

Side Effects

When using Lafaxor, you may experience unwanted effects (ADR).

The most unwanted effects related to the use of venlafaxin without seeing the corresponding ratio among the patients treated with Placebo are the nervous system disorders, including dizziness, dry mouth, insomnia, stress, sleeping. Gastrointestinal disorders include anorexia, constipation, nausea, ejaculation/pleasure disorders, sweating and weakness.

The regular level of these unwanted effects is related to the dose. Unwanted effects generally decrease in level and frequency when used for long term.

Instructions on how to handle ADR

When experiencing side effects of Lafaxor, it is necessary to stop using and notify the doctor or go to the nearest medical facility for timely treatment.

Warnings

Before using Lafaxor you need to read the user manual carefully and refer to the information below.

Contraindicated

LAFAXOR drug is contraindicated in the following cases:

Sensitive to any ingredients of the drug.

Used at the same time on patients who are using Monoamine inhibitors (Mao).

Patients with high cardiovascular risk (ventricular arrhythmia, uncontrolled hypertension ...).

Children under 18 years old (due to lack of clinical data).

Be cautious when using

need to take into account the risk of suicide in all depression patients. Only venlafaxin in small amounts to control patients well and reduce the possibility of overdose.

venlafaxin may interact with monoamine oxidase inhibitors (IMAO).

Unwanted effects, sometimes severe were recorded when starting Venlafaxin right after stopping taking an IMAO and when starting to take an IMAO right after stopping Venlafaxin. The reactions include trembling, dancing, sweating, nausea, vomiting, redness, dizziness, high fever with characteristics like malignant neurological syndrome, convulsions and death.

Medicine interactions lead to severe, sometimes dead reactions that have been recorded when used simultaneously or consecutive IMAO drugs and other antidepressants with pharmacological properties similar to venlafaxin. Do not use venlafaxin in combination with an IMAO or within 14 days after stopping with IMAO. Only IMao is used after stopping Venlafaxin for at least 7 days.

Increasing body temperature, spasticity, dancing, unstable neurological, mental changes include excessive excitement that leads to delusion, coma, and symptoms like malignant neurological syndrome that have been recorded when used simultaneously fast and selective Serotonin reabsorption inhibitors with IMAO. Increasing body temperature and epilepsy, sometimes death, has been reported when used simultaneously 3 -round antidepressants and IMAO.

Stop using vendaraxin

Clinical studies do not see the tendency of the symptoms of stopping drugs. However, when stopping the drug after the treatment period of 1 week or more, it is still advisable to gradually reduce the dose to minimize the risk of symptoms of stopping the drug. Patients who use venlafaxin for 6 weeks or more should be gradually reduced the dose within 1 week.

The ability to drive and operate machinery

as well as other antidepressants, must be cautious when driving or operating dangerous machines while taking Lafaxor.

Pregnancy

There are no adequate and well -controlled studies in pregnant women. Venlafaxin should not be used for pregnant women unless the benefits are greater than those that may occur. It is recommended that patients should notify physicians if they are pregnant or intend to get pregnant during treatment.

The period of breastfeeding

is unknown vendafaxin and its metabolites are excreted in milk or not. Therefore. Do not use vendafaxin for breastfeeding people.

Interactive drug

Monoamine inhibitors Oxidase: Contraindicated use of Venlafaxin for people who are using imao.

As with other drugs, it may be able to interact with many different mechanisms. Under 35% Venlafaxin and O-Desmethyl Venlafaxin are attached to plasma proteins. Therefore, there is no drug interaction due to competition associated with plasma proteins.

The risk of using Venlafaxin in combination with other medium -acting drugs has not been systematically evaluated (except for the drugs mentioned below). Therefore, it should be noted when using vendafaxin simultaneously with these drugs.

Venlafaxin and O-Desmethyl Venlafaxin's pharmacokinetics are not changed when used with Diazepam or Lithi for healthy volunteers. Venlafaxin does not affect Diazepam and Lithi's dynamics in these studies. The use of venlafaxin does not affect the effect on the mental of diazepam.

Cimetidin inhibits the initial metabolism of venlafaxin but does not affect the formation or excretion of O-Desmethyl Venlafaxin, more substances in the common circulation. In short, the synthetic pharmacological effect of Venlafaxin and O-Desmethyl Venlafaxin will only increase very slightly. There is no need to adjust the dose when used in combination with venlafaxin with cimetidine. However, for the elderly and patients with liver failure, simultaneous use of venlafaxin and cimetidin at the same time is still unclear what interactions will be and maybe more. Therefore, clinical monitoring should be indicated for these patients.

Symptoms obtained in clinical studies in patients using venlafaxin simultaneously with anti -hypertension drugs or hypoglycemic drugs have been re -evaluated to see if it is due to drug interaction. There is no evidence that proves not compatible with venlafaxin and other anti -hypertension as well as hypoglycemia.

There is no clinical research in evaluating the effectiveness of using Venlafaxin with other antidepressants.

Storage

Store in a dry place, avoid light, temperature not exceeding 30 ° C.

Other drugs

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.